Article

Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease

2021-06-15

Abstract excerpt

<h4>Background</h4> Characterization of neutralization antibodies to SARS-CoV-2 infection or vaccination in children and young adults with inflammatory bowel disease (IBD) receiving biologic therapies is crucial. <h4>Methods</h4> W e performed a prospective longitudinal cohort study evaluating SARS-CoV-2 Spike protein receptor binding domain (S-RBD) IgG positivity along with consistent clinical symptoms in patient...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e815a506-4a32-5f4a-a407-4fbf038e2a68
DOI: 10.1101/2021.06.12.21258810

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel DiseaseDOI 10.1101/2021.06.12.21258810Read

Typically asymptomatic but with robust antibody formation: Children’s unique humoral immune response to SARS-CoV-2Semantic proximity Read

Seroprevalence of Anti-Sars-CoV-2 Antibodies in Patients with Inflammatory Bowel DiseaseSemantic proximity Read

Serological response to COVID-19 vaccination in IBD patients receiving biologicsSemantic proximity Read

COVID-19 Vaccine-Induced Antibody Responses are Impaired in IBD Patients Treated with Infliximab or Tofacitinib, but not Thiopurines, Ustekinumab or VedolizumabSemantic proximity Read

COVID-19 Vaccine-Induced Antibody and T Cell Responses in Immunosuppressed Patients with Inflammatory Bowel Disease After the Third Vaccine DoseSemantic proximity Read

Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection.Semantic proximity Read

Patients with Inflammatory Bowel Disease on anti-Tumor Necrosis Factor Therapy Might be Predisposed to SARS-CoV-2 Variants Infection Even after Receiving a Third mRNA Vaccine DoseSemantic proximity Read

Favourable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapiesSemantic proximity Read

Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully predictive of sterilizing immunitySemantic proximity Read

Titers of antibodies the receptor-binding domain (RBD) of ancestral SARS-CoV-2 are predictive for levels of neutralizing antibodies to multiple variantsSemantic proximity Read

Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patientsSemantic proximity Read

Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.Semantic proximity Read